# Carcinoma, Hepatocellular trials: 553 new since Nov 2024

Updated November 9, 2026.

553 clinical studies in Carcinoma, Hepatocellular were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 87 have an industry sponsor and 454 are recruiting or about to. The newest, NCT07924943, was posted on November 9, 2026: Transarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular... (AIO-Studien-gGmbH).

## The full list

New Carcinoma, Hepatocellular clinical trials: 553 rows for $27.65, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 18 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/carcinoma-hepatocellular

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 553
- Industry sponsored: 87
- Recruiting or not yet: 454
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 553, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07924943 | Transarterial Chemoembolization (TACE) and Stereotactic Body Radiation (SBRT) in Patients With Hepatocellular Carcinoma (HCC) Prior to... | AIO-Studien-gGmbH | Not applicable | Recruiting | HCC - Hepatocellular Carcinoma | 44 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924943) |
| November 5, 2026 | NCT07919717 | NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCC | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Recurrent Hepatocellular Cancer | 35 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919717) |
| November 4, 2026 | NCT07917481 | A Clinical Study Evaluating the Safety and Efficacy of Ivonescimab as Second-line Treatment in Patients With Advanced Hepatocellular... | MedSIR | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), HCC - Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma (HCC) | 44 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917481) |
| November 4, 2026 | NCT07916376 | Characterizing Tumor Hypoxia With BOLD-MRI to Predict Y-90 Treatment Response | UNC Lineberger Comprehensive Cancer Center | Not applicable | Not yet recruiting | Hepatocellular Carcinoma, Liver Cancer | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07916376) |
| November 3, 2026 | NCT07911683 | Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma | BeOne Medicines | Phase 2 | Not yet recruiting | Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911683) |
| October 29, 2026 | NCT07904494 | Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular... | Assiut University | Observational | Not yet recruiting | Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable, Hepatocellular... | 294 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904494) |
| October 26, 2026 | NCT07895732 | Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma | University Health Network, Toronto | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 60 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895732) |
| October 26, 2026 | NCT07895342 | Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma | Radboud University Medical Center | Not applicable | Not yet recruiting | Hepatocellular Carcinoma Non-Resectable | 16 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895342) |
| October 21, 2026 | NCT07884877 | PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer | Samsung Medical Center | Phase 2 | Recruiting | Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming, Immunotherapy | 38 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884877) |
| October 20, 2026 | NCT07882056 | SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma | Peking University Cancer Hospital & Institute | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 33 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882056) |
| October 19, 2026 | NCT07880106 | Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Observational | Not yet recruiting | Lung Cancer Non-small Cell, Colorectal Cancer, Stomach Cancer, Hepatocellular Carcinoma, Breast Cancer | 2,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880106) |
| October 16, 2026 | NCT07878689 | Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma | University of Texas Southwestern Medical Center | Phase 1/2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 36 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878689) |
| October 16, 2026 | NCT07877220 | Estimating The Rate Of Complete Ablation (A0) With The Use Of Biomechanical Deformable Image Registration | M.D. Anderson Cancer Center | Not applicable | Not yet recruiting | Liver Tumors | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877220) |
| October 13, 2026 | NCT07872319 | Biomarkers Usefulness in the Screening of Hepatocellular Carcinoma in an European High-risk Cohort. | Hospital Universitario La Paz | Observational | Completed | Hepatocellular Carcinoma (HCC) | 417 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872319) |
| October 9, 2026 | NCT07867522 | Prevention of Bile Leakage After Liver Resection in Children | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Not applicable | Recruiting | Postoperative Bile Leak, Focal Liver Lesions | 12 | Russia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867522) |
| October 8, 2026 | NCT07866612 | Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma | West China Hospital | Not applicable | Not yet recruiting | Hepatocellular Carcinoma | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07866612) |
| October 7, 2026 | NCT07863258 | STRATHEP: AI-Driven Treatment Stratification for Advanced Hepatocellular Carcinoma | Universitaire Ziekenhuizen KU Leuven | Observational | Recruiting | Hepatocellular Carcinoma (HCC) | 280 | Belgium | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863258) |
| October 6, 2026 | NCT07861425 | Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard... | Acepodia Biotech, Inc. | Phase 1 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Metastatic, Hepatocellular Carcinoma Non-Resectable | 70 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861425) |
| September 30, 2026 | NCT07850882 | A Prospective Real-World Observational Study of Intratumoral Oncolytic Virus Injection Combined With Immune Checkpoint Inhibitors for... | Jie Yuan，MD | Observational | Recruiting | Colorectal Cancer (CRC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC) | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850882) |
| September 30, 2026 | NCT07849660 | Real-World Lenvatinib Sequencing in Unresectable Hepatocellular Carcinoma (uHCC) | Eisai Inc. | Observational | Active not recruiting | Carcinoma, Hepatocellular | 170 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849660) |
| September 30, 2026 | NCT07848750 | InstaSure™ Non-Invasive Finger-Press Test for Hepatocellular Carcinoma | Beijing Municipal Administration of Hospitals | Observational | Recruiting | Hepatocellular Carcinoma | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848750) |
| September 28, 2026 | NCT07845266 | Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable... | Beijing Gene Key Life Technology Co., Ltd | Phase 1 | Completed | Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma | 13 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845266) |
| September 24, 2026 | NCT07840092 | Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma | Tianjin Medical University Cancer Institute and Hospital | Observational | Recruiting | Hepatocellular Carcinoma (HCC) | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840092) |
| September 24, 2026 | NCT07839767 | Treatment Selection by 3D Bioprinting Liver Model to Prevent Liver Cancer Recurrence | The University of Hong Kong | Observational | Recruiting | HCC - Hepatocellular Carcinoma | 20 | Hong Kong | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839767) |
| September 24, 2026 | NCT07838415 | Multimodalomics-based Construction of Spatiotemporal Characteristics of Dynamic Liver Cancer Microenvironment to Characterize the Clinical... | Tongji Hospital | Observational | Recruiting | Hepatocellular Carcinoma (HCC), Treatment Response | 400 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838415) |
| September 23, 2026 | NCT07836712 | Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced... | University of Southern California | Phase 2 | Not yet recruiting | Advanced Hepatocellular Carcinoma, Advanced Melanoma, Locally Advanced Melanoma, Metastatic Melanoma, Stage III... | 46 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836712) |
| September 23, 2026 | NCT07836530 | Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma | BeOne Medicines | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma, Liver Cancer | 492 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836530) |
| September 23, 2026 | NCT07836309 | TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602) | Zhongda Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 596 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836309) |
| September 21, 2026 | NCT07832006 | Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma | Shunda Du | Phase 2 | Recruiting | Hepatocellular Carcinoma (HCC) | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832006) |
| September 21, 2026 | NCT07829926 | Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer | First Affiliated Hospital of Wenzhou Medical University | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829926) |
| September 18, 2026 | NCT07827807 | PEARL Trial: Partial TACE Enhancing Anti-tumor Response With Lenvatinib in Unresectable HCC | Chang Gung Memorial Hospital | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827807) |
| September 17, 2026 | NCT07825519 | Effectiveness of Enhanced Web-Based Health Education on Self-Care Practices and Quality of Life Among Patients With Hepatocellular... | University Medical Center Ho Chi Minh City (UMC) | Not applicable | Active not recruiting | Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization), Web-based Intervention, Quality of... | 252 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825519) |
| September 17, 2026 | NCT07824583 | A Study Evaluating a New Radiation Treatment Workflow (NGDS) | Varian, a Siemens Healthineers Company | Not applicable | Recruiting | Lung Cancer (Diagnosis), Liver Cancer, Adult, Pancreatic Cancer, Thoracic Cancers, Abdominal Cancer | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824583) |
| September 16, 2026 | NCT07823348 | JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma | 560 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823348) |
| September 11, 2026 | NCT07815054 | Efficacy Evaluation of Microwave Ablation Assisted by Diaphragm Hydrodissection for Hepatocellular Carcinoma and Comparative Analysis With... | The First Hospital of Jilin University | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815054) |
| September 10, 2026 | NCT07814014 | Real-world Insight Into Systemic Therapies for HCC: Single-center Study | Mansoura University | Observational | Recruiting | HCC - Hepatocellular Carcinoma | 1,000 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814014) |
| September 10, 2026 | NCT07813572 | ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma | 600 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813572) |
| September 10, 2026 | NCT07811687 | Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function | Northern Jiangsu People's Hospital | Observational | Recruiting | Liver Cirrhosis, HCC - Hepatocellular Carcinoma, Hypersplenism | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811687) |
| September 8, 2026 | NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | Tam Anh Research Institute | Observational | Recruiting | HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Gastric Carcinoma, Breast Cancer, Lung Cancer, Endometrial... | 162 | Vietnam | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808164) |
| September 8, 2026 | NCT07807475 | DNP-MRSI of HCC Metabolism to Predict Therapeutic Response | Abramson Cancer Center at Penn Medicine | Observational | Recruiting | Barcelona Clinic Liver Cancer (BCLC) Stage A, B or C HCC, Hepatocellular Carcinoma (HCC) | 232 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807475) |
| September 3, 2026 | NCT07801287 | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | HCC - Hepatocellular Carcinoma | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07801287) |
| August 31, 2026 | NCT07795437 | GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma | Peking University First Hospital | Not applicable | Recruiting | Hepatocellular Carcinoma (HCC) | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795437) |
| August 28, 2026 | NCT07793695 | Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma | Anhui Provincial Hospital | Phase 2 | Recruiting | Hepatocellular Carcinoma | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793695) |
| August 26, 2026 | NCT07786792 | Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCC | Shanghai Zhongshan Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786792) |
| August 24, 2026 | NCT07782632 | Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma | Anhui Provincial Hospital | Observational | Recruiting | Hepatocellular Carcinoma (HCC) | 467 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07782632) |
| August 24, 2026 | NCT07781176 | Different Acupoint Stimulation for Postoperative Gastrointestinal Dysfunction in Primary Liver Cancer Patients | Shanghai Zhongshan Hospital | Not applicable | Not yet recruiting | Primary Liver Cancer | 132 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781176) |
| August 21, 2026 | NCT07780357 | HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B | Beijing Friendship Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 2,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780357) |
| August 20, 2026 | NCT07776080 | Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 | Recruiting | HCC - Hepatocellular Carcinoma | 35 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776080) |
| August 19, 2026 | NCT07774247 | Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma | CHA University | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 51 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774247) |
| August 17, 2026 | NCT07768085 | Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT | Shengjing Hospital | Not applicable | Not yet recruiting | Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma, Cyst... | 40,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768085) |
| August 14, 2026 | NCT07764835 | Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC) | D'Or Institute for Research and Education | Observational | Not yet recruiting | Hepatocellular Carcinoma, Liver Cirrhosis, Chronic Hepatitis B, Metabolic Dysfunction-Associated Steatotic Liver... | 300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764835) |
| August 12, 2026 | NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | HCC - Hepatocellular Carcinoma | 288 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07761286) |
| August 12, 2026 | NCT07760012 | 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors | Peking University Third Hospital | Not applicable | Recruiting | Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer, Pancreatic Cancer, Ovarian Cancer... | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760012) |
| August 7, 2026 | NCT07751783 | Development and Dissemination of Exercise Prescription and Intervention for Cancer Populations | Kaohsiung Medical University Chung-Ho Memorial Hospital | Not applicable | Recruiting | Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Lung Cancer... | 150 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07751783) |
| August 6, 2026 | NCT07749859 | SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Advanced Unresectable Hepatocellular Carcinoma | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749859) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 5, 2026 | NCT07748481 | Comparison of the Therapeutic Efficacy of Non-touch Microwave Ablation, Tumor-puncture Microwave Ablation and Surgical Resection for... | The First Hospital of Jilin University | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 180 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748481) |
| August 4, 2026 | NCT07745153 | Novel Abdominal Compression Positioning Technique for Respiratory Motion Management in Liver Tumors | Southern Medical University, China | Observational | Completed | Liver Neoplasms, Carcinoma, Hepatocellular | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745153) |
| July 29, 2026 | NCT07734857 | Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma | Shanghai Zhongshan Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734857) |
| July 29, 2026 | NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | University of Oklahoma | Observational | Not yet recruiting | Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Cancer, Colon... | 2,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732686) |
| July 29, 2026 | NCT07732504 | AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation | Tongji Hospital | Not applicable | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 2,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07732504) |
| July 27, 2026 | NCT07729592 | Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | Sun Yat-sen University | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 44 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729592) |
| July 27, 2026 | NCT07727759 | CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure | Minia University | Observational | Recruiting | Post-Hepatectomy Liver Failure, Liver Failure, Liver Neoplasms, Carcinoma, Hepatocellular, Liver Metastases... | 1,070 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07727759) |
| July 24, 2026 | NCT07724951 | The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable... | Shanghai Zhongshan Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 400 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07724951) |
| July 21, 2026 | NCT07717437 | DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver... | Maastricht University Medical Center | Observational | Recruiting | Liver Cancer, Liver Metastases | 350 | Australia, Austria, Belgium, Canada, Germany, Netherlands, New Zealand, Norway... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07717437) |
| July 21, 2026 | NCT07716345 | Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer | Second Affiliated Hospital of Xi'an Jiaotong University | Observational | Not yet recruiting | Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma | 100 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716345) |
| July 20, 2026 | NCT07714538 | Breath Research Narrow Validation for Gastrointestinal Cancer Detection | Imperial College London | Observational | Recruiting | Oesophageal Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Ductal... | 1,000 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714538) |
| July 20, 2026 | NCT07714317 | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in... | Shanghai Zhongshan Hospital | Phase 1/2 | Not yet recruiting | Resectable Hepatocellular Carcinoma | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714317) |
| July 20, 2026 | NCT07713290 | A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma | Beijing Gene Key Life Technology Co., Ltd | Phase 1 | Active not recruiting | Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer | 6 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713290) |
| July 16, 2026 | NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | Royan Institute | Early phase 1 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 6 | Iran | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709299) |
| July 16, 2026 | NCT07707661 | Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor | Eastern Hepatobiliary Surgery Hospital | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocellular Carcinoma, Hepatic Hemangioma, Focal Nodular... | 350 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707661) |
| July 15, 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Martin Huellner | Phase 1/2 | Not yet recruiting | Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis, Thyroid Cancer, Breast Cancer... | 770 | Switzerland | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705074) |
| July 15, 2026 | NCT07704489 | San Raffaele Registry on Liver Cancer | IRCCS San Raffaele | Observational | Recruiting | Liver and Intrahepatic Biliary Tract Cancer | 4,000 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704489) |
| July 15, 2026 | NCT07704216 | Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer | Second Affiliated Hospital of Xi'an Jiaotong University | Observational | Not yet recruiting | Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704216) |
| July 15, 2026 | NCT07704203 | Preoperative 3D Magnetic Resonance Elastography for Predicting Surgical Risk in Patients Undergoing Hepatectomy | Second Affiliated Hospital of Xi'an Jiaotong University | Observational | Not yet recruiting | Hepatic Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocellular Carcinoma, Metastatic Hepatocellular Carcinoma | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704203) |
| July 14, 2026 | NCT07703735 | Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma | Seoung Hoon Kim | Observational | Enrolling by invitation | Liver Transplantation, Hepatocellular Carcinoma (HCC) | 371 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703735) |
| July 13, 2026 | NCT07700082 | HCC-MPDS Multimodal Deep Learning Prognostic Model for Resectable HCC | Anhui Provincial Hospital | Observational | Completed | Hepatocellular Carcinoma (HCC) | 555 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07700082) |
| July 9, 2026 | NCT07691762 | A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular... | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Not yet recruiting | Hepatocellular Carcinoma | 690 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691762) |
| July 9, 2026 | NCT07691645 | Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome | Xiang-Qian | Phase 2 | Not yet recruiting | HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause... | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691645) |
| July 8, 2026 | NCT07690683 | Patients With Hepatocellular Carcinoma (HCC) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Not applicable | Not yet recruiting | Hepatocellular Carcinoma, Hepatocellular Cancer, Liver Diseases, Liver Cancer | 52 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690683) |
| July 8, 2026 | NCT07689175 | Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma | University of Texas Southwestern Medical Center | Phase 2 | Recruiting | Hepatocellular Carcinoma (HCC) | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689175) |
| July 7, 2026 | NCT07687914 | A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 2 | Not yet recruiting | HCC - Hepatocellular Carcinoma | 50 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687914) |
| July 7, 2026 | NCT07687758 | Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained... | Siriraj Hospital | Observational | Completed | Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease, Hepatocellular Carcinoma (HCC) | 571 | Thailand | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07687758) |
| July 6, 2026 | NCT07685548 | AI-Driven Tumor Response Evaluation for Solid Tumors | Shanghai Zhongshan Hospital | Observational | Not yet recruiting | Solid Tumor Cancer, Neoplasms, Hepatocellular Carcinoma | 6,120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685548) |
| July 2, 2026 | NCT07682454 | Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin | University of California, San Francisco | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Liver Cancer, Adult | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682454) |
| July 2, 2026 | NCT07681817 | Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver... | Tianjin Medical University Cancer Institute and Hospital | Not applicable | Not yet recruiting | Liver Cancer, Adult | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681817) |
| July 1, 2026 | NCT07679061 | First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE) | Bristol-Myers Squibb | Observational | Recruiting | Unresectable Hepatocellular Carcinoma | 200 | Japan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679061) |
| July 1, 2026 | NCT07677774 | GPC3-Targeted PET/CT in Hepatocellular Carcinoma | The First Affiliated Hospital of Xiamen University | Not applicable | Recruiting | Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07677774) |
| June 30, 2026 | NCT07675187 | HCC Risk and Monitoring in Patients With Type 2 Diabetes | National Taiwan University Hospital | Not applicable | Not yet recruiting | Type 2 Diabetes (T2DM), Hepatocellular Carcinoma (HCC) | 2,400 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07675187) |
| June 25, 2026 | NCT07669727 | A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning. | Boston Scientific Corporation | Observational | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 140 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669727) |
| June 25, 2026 | NCT07669597 | Comparison of Atezolizumab/Bevacizumab Versus Durvalumab/Tremelimumab (STRIDE) Protocols in Locally Advanced or Metastatic Hepatocellular... | Sohag Oncology Center | Observational | Active not recruiting | Locally Advanced or Metastatic Hepatoceullar Carcinoma | 50 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669597) |
| June 25, 2026 | NCT07668570 | SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma | Hebei Medical University Fourth Hospital | Phase 4 | Not yet recruiting | HCC - Hepatocellular Carcinoma | 36 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07668570) |
| June 25, 2026 | NCT07667608 | Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting... | Assiut University | Observational | Not yet recruiting | Cirrhosis of the Liver, Ascites, Pleural Effusion Disorder, Hepatocellular Carcinoma (HCC), Sarcopenia, Diaphragm... | 120 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07667608) |
| June 23, 2026 | NCT07664007 | Effects of EPA Supplementation on Patients With Unresectable Hepatocellular Carcinoma. | Instituto de Investigación Sanitaria Aragón | Not applicable | Completed | Hepatocellular Carcinoma | 18 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07664007) |
| June 23, 2026 | NCT07663487 | A Study Evaluating the Safety and Efficacy of Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres to... | Sirtex Medical | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 78 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07663487) |
| June 22, 2026 | NCT07658833 | TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Observational | Recruiting | Hepatocellular Carcinoma (HCC) | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658833) |
| June 22, 2026 | NCT07658586 | AI Multimodal Model for Liver Cancer Diagnosis and Prognosis | Guangxi Medical University | Observational | Active not recruiting | Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma (Icc) | 600 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658586) |
| June 18, 2026 | NCT07658105 | Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Active not recruiting | HCC - Hepatocellular Carcinoma | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658105) |
| June 18, 2026 | NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | Base Therapeutics (Shanghai) Co., Ltd. | Early phase 1 | Not yet recruiting | Hepatocellular Carcinoma (HCC), Ovarian Cancer, Malignant Ascites | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657416) |
| June 18, 2026 | NCT07657273 | Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 | Not yet recruiting | Hepatocellular Carcinoma | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657273) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Tianjin Medical University Cancer Institute and Hospital | 15 | September 24, 2026 |
| Shanghai Zhongshan Hospital | 14 | November 5, 2026 |
| Tongji Hospital | 14 | September 24, 2026 |
| Sun Yat-sen University | 11 | July 27, 2026 |
| West China Hospital | 10 | October 8, 2026 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 10 | May 22, 2026 |
| Zhongda Hospital | 9 | September 23, 2026 |
| Fudan University | 8 | February 17, 2026 |
| Anhui Provincial Hospital | 7 | August 28, 2026 |
| Peking Union Medical College Hospital | 7 | May 15, 2026 |
| Nanfang Hospital, Southern Medical University | 7 | May 4, 2026 |
| Seoul National University Hospital | 7 | March 17, 2026 |
| The First Hospital of Jilin University | 6 | September 11, 2026 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 6 | July 8, 2026 |
| AstraZeneca | 6 | June 16, 2026 |
| Assistance Publique - Hôpitaux de Paris | 6 | June 5, 2026 |
| First Affiliated Hospital, Sun Yat-Sen University | 6 | May 12, 2026 |
| Beijing Tsinghua Chang Gung Hospital | 6 | April 20, 2026 |
| National Taiwan University Hospital | 5 | June 30, 2026 |
| Second Affiliated Hospital of Guangzhou Medical University | 5 | June 18, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 194 | October 29, 2026 |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 124 | November 5, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 111 | November 9, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 46 | October 6, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 29 | October 16, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 20 | October 26, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 11 | June 25, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 9 | July 16, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 9 | March 24, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 239 | November 5, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 70 | November 4, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 31 | July 15, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 28 | October 21, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 23 | June 9, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 18 | August 7, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 14 | July 21, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 13 | October 29, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 12 | October 26, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 12 | October 13, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 12 | July 21, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 11 | November 9, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 9 | October 26, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 8 | October 7, 2026 |
| [Hong Kong](https://specstream.ai/data/clinical-trials/country/hong-kong) | 8 | September 24, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 8 | July 1, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 7 | February 6, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 6 | July 21, 2026 |
| [Austria](https://specstream.ai/data/clinical-trials/country/austria) | 5 | July 21, 2026 |
| [Switzerland](https://specstream.ai/data/clinical-trials/country/switzerland) | 5 | July 21, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 5 | June 16, 2026 |
| [Thailand](https://specstream.ai/data/clinical-trials/country/thailand) | 4 | July 7, 2026 |
| [India](https://specstream.ai/data/clinical-trials/country/india) | 4 | February 27, 2026 |
| [Vietnam](https://specstream.ai/data/clinical-trials/country/vietnam) | 3 | September 17, 2026 |
| [Norway](https://specstream.ai/data/clinical-trials/country/norway) | 3 | July 21, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).